Ascendis Pharma AS (ASND)
125.61
+0.33
(+0.26%)
USD |
NASDAQ |
Nov 04, 16:00
125.66
+0.06
(+0.04%)
After-Hours: 20:00
Ascendis Pharma Revenue (Quarterly): 38.76M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 38.76M |
| March 31, 2024 | 104.16M |
| December 31, 2023 | 148.29M |
| September 30, 2023 | 52.30M |
| June 30, 2023 | 51.68M |
| March 31, 2023 | 36.08M |
| December 31, 2022 | 23.41M |
| September 30, 2022 | 15.40M |
| June 30, 2022 | 6.562M |
| March 31, 2022 | 7.662M |
| December 31, 2021 | 5.601M |
| September 30, 2021 | 1.312M |
| June 30, 2021 | 1.232M |
| March 31, 2021 | 0.8989M |
| December 31, 2020 | 0.6379M |
| September 30, 2020 | 3.224M |
| June 30, 2020 | 1.582M |
| March 31, 2020 | 2.455M |
| December 31, 2019 | 2.776M |
| September 30, 2019 | 2.494M |
| June 30, 2019 | 3.607M |
| March 31, 2019 | 6.150M |
| Date | Value |
|---|---|
| December 31, 2018 | 12.00M |
| September 30, 2018 | 0.0233M |
| June 30, 2018 | 0.0215M |
| March 31, 2018 | 0.0344M |
| December 31, 2017 | 0.3297M |
| September 30, 2017 | 0.5102M |
| June 30, 2017 | 0.4885M |
| March 31, 2017 | 0.3963M |
| December 31, 2016 | 1.125M |
| September 30, 2016 | 1.305M |
| June 30, 2016 | 1.283M |
| March 31, 2016 | 1.388M |
| December 31, 2015 | 2.163M |
| September 30, 2015 | 2.353M |
| June 30, 2015 | 2.147M |
| March 31, 2015 | 2.348M |
| December 31, 2014 | 3.529M |
| September 30, 2014 | 4.307M |
| June 30, 2014 | 5.367M |
| March 31, 2014 | 5.472M |
| December 31, 2013 | 7.568M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.6379M
Minimum
Dec 2020
148.29M
Maximum
Dec 2023
26.53M
Average
6.562M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
| Evaxion Biotech AS | 3.017M |
| Adaptimmune Therapeutics PLC | 128.23M |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | -- |
| Genfit SA | 15.36M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -117.77M |
| Total Expenses (Quarterly) | 182.25M |
| EPS Diluted (Quarterly) | -2.057 |
| Enterprise Value | 7.950B |
| Gross Profit Margin (Quarterly) | 68.15% |
| Profit Margin (Quarterly) | -303.9% |
| Earnings Yield | -7.44% |
| Normalized Earnings Yield | -7.443 |